Nalbuphine is a phenanthrene derivative with mixed opioid agonist and antagonist activity (agonist at kappa opiate receptor; partial antagonist at ? receptor). It inhibits the ascending pain pathways, alters the perception of and response to pain by binding to opiate receptors in the CNS. It also produces generalised CNS depression.
Radirif IM/IV Injection
(in Injection form)
Adjunct in balanced anaesthesia: Adult: Induction: 0.3-3 mg/kg over 10-15 min. Maintenance: 0.25-0.5 mg/kg as single admin if required.
Obstetrical analgesia during labor and delivery: 0.3-1 mg/kg over 10-15 minutes with maintenance dose of 0.25-0.5 mg/kg in single intravenous administration as required.
Intra-operative analgesia: 0.25-0.5 mg/kg at 30 minutes intervals.
Myocardial infarction: by slow intravenous injection 10-20 mg repeated after 30 minutes if necessary.
Moderate to severe pain:
Adult: IM/IV/SC: 10-20 mg 3-6 hrly as required. Non-opioid-tolerant patients: Max single dose: 20 mg. Max daily dose: 160 mg.
Manufacturer: Square Pharmaceutical Ltd.